Larissa Camejo, MD
Ophthalmology · Palm Beach Gardens, FLNPI 1447286190
Payments from drug & device makers
Across 479 payments — averaging $510.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$80K
- Aerie Pharmaceuticals, Inc.$64K
- Sight Sciences, Inc.$24K
- Nova Eye, Inc.$22K
- Glaukos Corporation$14K
- NEW World Medical,inc.$13K
- plus $27K from 27 others
What the payments were for
- Consulting fees$105,56943%
- Speaking & faculty fees$100,77341%
- Travel & lodging$19,2458%
- Food & beverage$18,4268%
- Education$2220%
- Gifts$390%
- Entertainment$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 131 | $80,224 |
| Aerie Pharmaceuticals, Inc. | 46 | $64,171 |
| Sight Sciences, Inc. | 43 | $24,268 |
| Nova Eye, Inc. | 5 | $22,090 |
| Glaukos Corporation | 48 | $13,964 |
| NEW World Medical,inc. | 26 | $12,516 |
| Alcon | 43 | $10,703 |
| Johnson & Johnson Surgical Vision, Inc. | 16 | $6,168 |
| Lumibird Medical Inc. | 2 | $3,063 |
| Iridex Corporation | 2 | $1,525 |
| Bausch & Lomb Americas Inc. | 12 | $1,268 |
| Sun Pharmaceutical Industries Inc. | 12 | $658 |
| Ivantis, Inc | 1 | $500 |
| Oyster Point Pharma, Inc. | 12 | $390 |
| Mallinckrodt Hospital Products Inc. | 8 | $349 |
| Thea Pharma Inc. | 7 | $324 |
| Tarsus Pharmaceuticals, Inc. | 10 | $276 |
| Kala Pharmaceuticals, Inc. | 3 | $269 |
| Omeros Corporation | 5 | $264 |
| Novartis | 7 | $262 |
| Harrow Eye, LLC | 8 | $229 |
| Eyevance Pharmaceuticals LLC | 1 | $129 |
| Rayner Intraocular Lenses Limited | 4 | $125 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $123 |
| Amgen(2 entities) | 5 | $102 |
| Ocular Therapeutix, Inc. | 5 | $89 |
| ANI Pharmaceuticals, Inc. | 3 | $72 |
| Carl Zeiss Meditec USA, Inc. | 2 | $60 |
| Dompe US, Inc. | 2 | $57 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Astellas Pharma US Inc | 1 | $23 |
| Oculus Surgical Inc. | 3 | $17 |
| Lensar, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$71,723
- Rhopressa$59,821
- DURYSTA$46,957
- XEN GLAUCOMA TREATMENT SYSTEM$32,477
- OMNI(R) SURGICAL SYSTEM (US)$15,901
- Kahook Dual Blade$10,961
- Clearpath$10,961
- Ahmed Glaucoma Valve$10,961
- Streamline$10,961
- iDose$10,745
- Via360$10,242
- OMNI$7,614
- Tecnis Simplicity$5,729
- Tecnis IOL$5,483
- TANGO OPTIMO$3,063
- SIMBRINZA$2,070
- LUMIGAN$1,547
- SION SURGICAL INSTRUMENT$990
- VYZULTA$850
- Hydrus$500
How this compares
$244,334 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 120 | $114,099 |
| XiidraLifitegrast | 81 | $77,340 |
| RocklatanNetarsudil Mesylat/Latanoprost | 151 | $65,389 |
| LumiganBimatoprost | 146 | $60,465 |
| VyzultaLatanoprostene Bunod | 146 | $53,019 |
| RhopressaNetarsudil Mesylate | 134 | $49,517 |
| CombiganBrimonidine Tartrate/Timolol | 145 | $45,880 |
| Alphagan PBrimonidine Tartrate | 111 | $28,552 |
| IlevroNepafenac | 60 | $24,174 |
| Prednisolone Acetate | 301 | $11,924 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 54 | $11,177 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 88 | $10,993 |
| ProlensaBromfenac Sodium | 25 | $8,780 |
| Brimonidine Tartrate | 395 | $8,064 |
| Pilocarpine Hcl | 131 | $7,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $80,224 | $248,996522 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,268 | $130,358227 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $64,171 | $114,906285 claims |
| NovartisIlevro | $262 | $24,17460 claims |
| AlconSimbrinza | $10,703 | $11,17754 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $123 | $8,78025 claims |
| Thea Pharma Inc.Iyuzeh | $324 | $6,58018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Palm Beach Gardens
- Mark MilnerPalm Beach Gardens$1.2M
- Jorge FortunPalm Beach Gardens$940K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.